相似文献
1
Insulin resistance and steatosis in hepatitis C virus infection.
Gut. 2005 Jul;54(7):903-6. doi: 10.1136/gut.2004.059873.
2
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
Gut. 2005 Jul;54(7):1003-8. doi: 10.1136/gut.2004.050302.
3
[Pathomechanism of metabolic disorders in HCV infection].
Przegl Epidemiol. 2006;60(4):701-5.
4
Steatosis in chronic hepatitis C: why does it really matter?
Gut. 2006 Jan;55(1):123-30. doi: 10.1136/gut.2005.069757.
5
Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C.
Minerva Gastroenterol Dietol. 2006 Jun;52(2):125-34.
6
Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Gut. 2011 Oct;60(10):1394-402. doi: 10.1136/gut.2010.222844. Epub 2011 Jan 26.
7
Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.
Aliment Pharmacol Ther. 2009 Jul;30(1):61-70. doi: 10.1111/j.1365-2036.2009.03995.x. Epub 2009 Mar 9.
8
Steatosis and insulin resistance in response to treatment of chronic hepatitis C.
J Viral Hepat. 2012 Jan;19 Suppl 1:42-7. doi: 10.1111/j.1365-2893.2011.01523.x.
9
Hepatitis C virus diversity and hepatic steatosis.
J Viral Hepat. 2013 Feb;20(2):77-84. doi: 10.1111/jvh.12035. Epub 2012 Nov 29.
10
The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance.
Nutr Res. 2013 Jan;33(1):27-33. doi: 10.1016/j.nutres.2012.11.007. Epub 2012 Dec 20.
引用本文的文献
1
Directly acting antivirals improve insulin resistance in nondiabetic patients with hepatitis C: a systematic review and meta-analysis.
Ann Med Surg (Lond). 2025 Feb 28;87(4):2255-2262. doi: 10.1097/MS9.0000000000003081. eCollection 2025 Apr.
2
Alcohol and hepatocellular carcinoma.
BMJ Open Gastroenterol. 2019 Apr 3;6(1):e000260. doi: 10.1136/bmjgast-2018-000260. eCollection 2019.
3
Alcoholic liver disease and hepatitis C virus infection.
World J Gastroenterol. 2016 Jan 28;22(4):1411-20. doi: 10.3748/wjg.v22.i4.1411.
4
Effect of soy protein supplementation in patients with chronic hepatitis C: a randomized clinical trial.
World J Gastroenterol. 2012 May 14;18(18):2203-11. doi: 10.3748/wjg.v18.i18.2203.
5
The impact of host metabolic factors on treatment outcome in chronic hepatitis C.
Gastroenterol Res Pract. 2012;2012:420156. doi: 10.1155/2012/420156. Epub 2012 Apr 22.
6
Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes.
Clinics (Sao Paulo). 2012;67(3):219-23. doi: 10.6061/clinics/2012(03)03.
7
Chemokine antagonism in chronic hepatitis C virus infection.
J Clin Invest. 2011 Jan;121(1):25-7. doi: 10.1172/JCI45610. Epub 2010 Dec 22.
8
Treatment responses in Asians and Caucasians with chronic hepatitis C infection.
World J Gastroenterol. 2008 Jun 7;14(21):3416-20. doi: 10.3748/wjg.14.3416.
9
Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome.
World J Gastroenterol. 2007 Dec 14;13(46):6213-8. doi: 10.3748/wjg.v13.i46.6213.
10
Topological and evolutional relationships between HCV core protein and hepatic lipid vesicles: studies in vitro and in conditionally transgenic mice.
World J Gastroenterol. 2007 Jul 7;13(25):3472-7. doi: 10.3748/wjg.v13.i25.3472.
本文引用的文献
1
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
Gut. 2005 Jul;54(7):1003-8. doi: 10.1136/gut.2004.050302.
2
Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients.
J Clin Endocrinol Metab. 2005 Apr;90(4):2240-3. doi: 10.1210/jc.2004-1266. Epub 2005 Jan 11.
3
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees.
J Virol. 2004 Dec;78(24):13779-92. doi: 10.1128/JVI.78.24.13779-13792.2004.
4
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.
Am J Pathol. 2004 Nov;165(5):1499-508. doi: 10.1016/S0002-9440(10)63408-6.
5
Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms.
Mol Cell Biol. 2004 Jun;24(12):5434-46. doi: 10.1128/MCB.24.12.5434-5446.2004.
6
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
J Hepatol. 2004 Mar;40(3):484-90. doi: 10.1016/j.jhep.2003.11.004.
7
Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury.
Hepatology. 2004 May;39(5):1230-8. doi: 10.1002/hep.20179.
8
Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.
Gastroenterology. 2004 Mar;126(3):840-8. doi: 10.1053/j.gastro.2003.11.056.
9
Fibrosis progression in chronic hepatitis C virus infection.
Gut. 2004 Mar;53(3):318-21. doi: 10.1136/gut.2003.026393.
10
Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance.
Nat Med. 2004 Mar;10(3):268-74. doi: 10.1038/nm995. Epub 2004 Feb 8.
Zotero 插件